Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects

Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects

Vaccination toward SARS-CoV-2 reduced mortality and ‘boosters’ are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home “San Giuseppe Moscati” who had re...

Full description

Bibliographic Details
Main Authors: Fabio Borgonovo, Carlo Alberto Stangalini, Carmine Tinelli, Chiara Mariani, Davide Mileto, Maria Vittoria Cossu, Laura Abbati, Lara Bilardo, Gloria Gagliardi, Miriam Cutrera, Martina Pellicciotta, Luciana Armiento, Gianfranco Dedivitiis, Amedeo F. Capetti, Giuliano Rizzardini
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
covid-19
sars-cov-2
spike
igg
antibody
kinetics
decline
vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2022.2060018

Internet

http://dx.doi.org/10.1080/21645515.2022.2060018

Similar Items